GlassScriptPhysician profile
Molly Brotherson
NPI 1578598132
$4,204.06
in general payments reported to CMS, 2019-2025
28 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $559 · 2022: $1,004 · 2023: $1,095 · 2024: $990 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,641.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $516.39 | 2021-2024 | Jynarque |
| Travere Therapeutics, INC. | $435.60 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $394.47 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $360.68 | 2021-2025 | Lokelma, Farxiga |
| Glaxosmithkline, LLC. | $352.73 | 2021-2025 | Benlysta |
| Amgen INC. | $299.40 | 2021-2025 | Tavneos, Krystexxa |
| Ani Pharmaceuticals, INC. | $274.63 | 2022-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $228.71 | 2022-2025 | Veltassa |
| Horizon Therapeutics Plc | $203.21 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.06 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $122.20 | 2023-2024 | Jardiance |
| Fresenius USA Marketing, INC. | $115.19 | 2022-2024 | Velphoro, Korsuva |
| Rhythm Pharmaceuticals, INC. | $110.32 | 2022-2023 | Imcivree |
| Novo Nordisk INC | $98.03 | 2022-2025 | Rybelsus, Ozempic, Rivfloza |
| Baxter Healthcare | $79.62 | 2023-2024 | Renal - Pd, Renal - Chronic |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $77.06 | 2022-2024 | Acthar |
| Ardelyx, INC. | $76.55 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $58.06 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $54.50 | 2022-2025 | Tarpeyo |
| Cormedix INC. | $42.58 | 2024 | Defencath |
| Opko Pharmaceuticals, LLC | $36.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.23 | 2023 | Gattex |
| Boston Scientific Corporation | $23.70 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.84 | 2022 | |
| Arbor Pharmaceuticals, INC. | $17.04 | 2021 | |
| Daiichi Sankyo INC. | $14.55 | 2024 | Injectafer |
| Aurinia Pharma U.S., INC. | $14.17 | 2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $14.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Brotherson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.